https://sms.carm.es/ricsmur/handle/123456789/17704 2026-11-12T02:58:10Z https://sms.carm.es/ricsmur/handle/123456789/29211 Clinical Course and Predictors of Biologic Therapy, Hospitalisation and Surgery: A Five-Year Prospective Study in Newly Diagnosed Inflammatory Bowel Disease. Garre, Ana; Nunez-Ortiz, Andrea; Rubio, Saioa; Diz-Lois-Palomares, María-Teresa; Riestra, Sabino; Alonso-Galan, Horacio; Fernández-Salgado, Estela; Ferreiro-Iglesias, Rocio; Vela, Milagros; Ponferrada-Diaz, Angel; Sánchez-Rodríguez, Eugenia; Hernández, Vicent; Arias-García, Lara; Barrio, Jesús; Huguet, José-María; Ginard, Daniel; Rivero, Montserrat; Vera, Isabel; Alonso-Abreu, Inmaculada; Benitez, José-Manuel; Aguas, Mariam; Rodríguez-Lago, Iago; Calvet, Xavier; Fernández-Salazar, Luis; Echarri, Ana; Arroyo, María-Teresa; Navarro-Llavat, Merce; Vega, Pablo; Sierra, Mónica; Guerra-del-Rio, Elena; Vicente, Raquel; Casanova, María-José; Navarro, Pablo; de-Zarate, Jone-Ortiz; Trastoy, Pilar-Varela; Spicakova, Katerina; Gutiérrez, Ana; Martin-Arranz, María-Dolores; Pinero, Concepcion; Hernández-Martínez, Alvaro; Torrella-Cortés, Emilio; Marrero, José-Miguel; Lorente-Poyatos, Rufo-H; Marti-Romero, Lidia; Bosch, Orencio; Duque, José-María; Aceituno, Montserrat; Fernández, Hipolito; Crespo-Suarez, Belen; Fuentes-Coronel, Ana-María; Pozzati, Liliana; Robledo, Pilar; Sese-Abizanda, Eva; Herreros-Martínez, Belen; Jiménez, Nuria; López-Serrano, Pilar; Sampedro, Manuela-Josefa; Bermejo, Fernando; Lucendo, Alfredo-J; Munoz-Vicente, Margarita; Menacho, Margarita; Ramirez-Palanca, José-Joaquin; Camargo, Raquel; Carmona, Amalia; Torra-Alsina, Sandra; Calafat, Margalida; Forcelledo, José-Luis-F; Nerin-de-la-Puerta, Juan; Nicolás-de-Prado, Isabel; Opio, Veronica; Ber, Yolanda; Bouhmidi, Abdel; Abraldes-Bechiarelli, Alfredo; Castano-Milla, Carlos; Cruz, Noelia; Gordillo, Jordi; Sapina, Amparo; López, Alina; Rodríguez-Mondejar, Silvia; Novella-Duran, María-Teresa; Botella, Belen; Kutz, Marcos; Kolle, Lilyan; Marin-Jiménez, Ignacio; Martínez-Cerezo, Francisco-J; Irisarri, Rebeca; Iyo, Eduardo; Roncero, Oscar; Sabat, Miriam; Torres-Domínguez, Yolanda; Ledezma, Cesar; Zapata, Eva-María; Alcala, María-José; Lluis, Laia; Martínez-Pascual, Cristina; Blazquez-Gómez, Isabel; Hernández, Luis; Mata, Laura; Monrobel, Ana; Hernández-Camba, Alejandro; Maroto, Nuria; Tejada, María; Galve, María-Luisa; Montealegre, María; Hervias, Daniel; Soler, Marta; Gómez-Valero, José-Antonio; Barreiro-de-Acosta, Manuel; Soto-Escribano, Pilar; Cabriada, José-Luis; Ceballos, Daniel; Esteve, María; García-Rodríguez, Alba; Royo, Vanesa; Gomollon, Fernando; Verdejo-Gil, Cristina; Nos, Pilar; de-Francisco, Ruth; García, María-José; Duenas-Sadornil, Carmen; Rodríguez, Cristina; Sicilia, Beatriz; Fernández-Felix, Borja-M; Gisbert, Javier-P; Chaparro, María AIMS: This study aimed to describe the characteristics of newly diagnosed inflammatory bowel disease (IBD) patients and to analyse their clinical course within the first 5 years after diagnosis, including the need for surgery, hospitalisations and treatments. METHODS: This prospective and large multicentre incident cohort registry in Spain enrolled adults diagnosed with Crohn's disease (CD), ulcerative colitis (UC) or unclassified IBD (IBD-U) in 2017 and followed them for 5 years. RESULTS: A total of 3301 patients were enrolled: 1526 with CD, 1633 with UC and 142 with IBD-U. Their median age at diagnosis was 43 years (interquartile range 31-56) and approximately 50% were male. Within 5 years post-diagnosis, 30% received biologics or JAK inhibitors (JAKi), 34% were hospitalised at least once and 9% underwent surgery. The cumulative incidence of biologic/JAKi treatment, hospitalisations and surgeries was higher among CD patients. Use of biologics/JAKi correlated with a more aggressive CD phenotype, greater UC extent and younger age at diagnosis. Biologics/JAKi treatment was associated with lower hospitalisation risk in both CD (Hazard ratio [HR] = 0.4, 95% confidence interval [CI] = 0.2-0.6) and UC patients (HR = 0.5, 95% CI = 0.2-0.9). However, it was not associated with the risk of abdominal surgery in CD but was linked to an increased risk of surgery in UC (HR = 11.9, 95% CI = 4.6-30.4). CONCLUSIONS: This large multicentre cohort demonstrated a higher use of biologics/JAKi during the first 5 years after IBD diagnosis than previously reported. Treatment with biologics/JAKi was associated with reduced risk of hospitalisation. However, under current clinical practice patterns, this therapeutic approach did not translate into lower risk of abdominal surgery. 2026-10-11T00:00:00Z https://sms.carm.es/ricsmur/handle/123456789/29210 ¿Oportunidades perdidas? Conocimientos y actitudes de los médicos y las médicas de familia en la prevención y diagnóstico del virus de inmunodeficiencia humana Barceló-Barceló, Inmaculada-Concepción; Castillo-Sánchez, Miguel; Ruiz-Merino, Guadalupe Objetivos: identificar factores asociados a la adhesión de las y los especialistas en Medicina Familiar y Comunitaria (MFyC) a las recomendaciones vigentes en prevención y diagnóstico precoz de la infección por el virus de la inmunodeficiencia humana (VIH). Métodos: estudio observacional descriptivo transversal realizado en tres zonas básicas de salud en Atención Primaria (AP). Participaron 73 especialistas y residentes de MFyC mediante cuestionario autocumplimentado. Se recogieron variables sociodemográficas, actitudes, formación y conocimientos sobre VIH. Resultados: respondieron el 83,5% de las y los profesionales (n = 61). La edad presentó una mediana de 42 años (rango intercuartílico [RIC]: 28-60), y la experiencia profesional, de 16 años (RIC: 3-33). El 80% solicitó la prueba ante sospecha de infección de transmisión sexual (ITS) o pareja serodiscordante. Más del 60% refirió no solicitarla ante condiciones indicadoras de VIH o a personas procedentes de regiones con mayor prevalencia de VIH como África 2026-06-15T00:00:00Z https://sms.carm.es/ricsmur/handle/123456789/29177 Long-term Effectiveness, Treatment Persistence, and Timing of Virological Failure With Long-Acting Cabotegravir Plus Rilpivirine in Real-World HIV Care: RELATIVITY Cohort Buzon, Luis; Cabello-Clotet, Noemi; Montes, María-Luisa; Galindo, María-José; Maria-Martínez, Rosa; Santacreu, Mireia; Remedios-Aleman, María; Torralba, Miguel; Fanjul, Francisco; Gutiérrez-Cuadra, Manuel; Rodríguez, Adrián; Crusells, María-José; Navarro, María; Aguilera-García, María; Hidalgo-Tenorio, Carmen; Morano, Luis-Enrique; Vinuesa, David; Bernal-Morell, Enrique; de-Andres, Carlos; Pernas, Hadrian; Tiraboschi, Juan; Bendala, Alejandro; Vivancos, María-Jesús; Diez, Cristina; Soria, Guillermo; Pérez, Desire; Cairo, Mireia; Romero, Alberto; Cabo, Rebeca; Soler, Josefa; Sepulveda, María-Antonia; Bravo-Urbieta, Joaquín; Escrich, Cristina; Ferreira, Eva; Valentin, Beatriz; Muelas, Magdalena; Lucas-Dato, Ana; Gómez, Albert; Cerezales, Ana; Losa, Juan-Emilio; Sanz, Jose; Masia, Mar; Corte-García, Juan-José; Antoli, Ana; Gainzarain, Juan-Carlos; Estebanez, Miriam; Barragan, Patricia; Clavero, Marta; Ferrero, Oscar Background Long-acting injectable cabotegravir plus rilpivirine (CAB + RPV LA) is an established maintenance option for virologically suppressed people with human immunodeficiency virus-1 (HIV-1), but long-term real-world persistence and virological failure (VF) data remain limited. Methods RELATIVITY is an ongoing nationwide ambispective multicenter cohort of adults with HIV who switched from suppressive oral antiretroviral therapy to CAB + RPV LA in routine care in Spain. Data through 1 March 2026 were analyzed. The outcomes were virological suppression, treatment persistence, protocol-defined VF, and time to discontinuation-related events. Virological failure was defined as 2 consecutive HIV-1 RNA values ?200 copies/mL or 1 value ?500 copies/mL prompting discontinuation. Results Among 3349 participants, 3343 had valid follow-up dates; the median follow-up was 25.1 months (19.3-30.8). Virological suppression was documented in 3197/3349 (95.5%) overall and 3197/3309 (96.6%) with an evaluable closest viral load; 40 (1.2%) lacked an evaluable value. Injection adherence was ?90% in 3257/3280 (99.3%) evaluable participants. Overall, 2979/3349 (89.0%) remained on CAB + RPV LA. Virological failure occurred in 28/3349 (0.8%); 20/28 (71.4%) occurred within the first 12 months after switching. Emergent integrase strand transfer inhibitor and/or nonnucleoside reverse transcriptase inhibitor resistance was detected in 19/28 VF cases, and 24/28 achieved virological suppression after switching to oral therapy. Treatment-limiting injection-site reactions and systemic adverse events occurred in 2.4% and 1.6%, respectively. Conclusions Long-acting injectable cabotegravir plus rilpivirine showed high virological suppression and persistence beyond 2 years in routine care. Virological failure was uncommon and clustered mainly within 12 months, supporting early virological monitoring and prompt resistance-guided management. 2026-09-29T00:00:00Z https://sms.carm.es/ricsmur/handle/123456789/29175 Biochemical analysis of fine needle aspiration washout fluid: Redefining diagnostic precision in thyroid and parathyroid cytopathology Agüera-Sánchez, Alfonso; García-Molina, Francisco; Martínez-Martínez, Irene; Martínez-Díaz, Francisco 2026-10-16T00:00:00Z